Overprescription of short-acting β2-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study

Simple item page
dc.contributor.authorAl Zaabi A.
dc.contributor.authorBusaidi N.
dc.contributor.authorAl Mutairy S.
dc.contributor.authorYorgancıoğlu A.
dc.contributor.authorAksu K.
dc.contributor.authorAl-Jahdali H.
dc.contributor.authorWali S.
dc.contributor.authorElsayed M.
dc.contributor.authorBeekman M.J.H.I.
dc.date.accessioned2024-07-22T08:05:01Z
dc.date.available2024-07-22T08:05:01Z
dc.date.issued2022
dc.description.abstractBackground: Although short-acting β2-agonist (SABA) overuse is associated with poor treatment outcomes, data on SABA use in the Middle East are lacking. Research design and methods: In this cross-sectional study in patients (aged ≥12 years) with asthma, data on disease characteristics and asthma treatments were collected from the Middle Eastern cohort of the SABA use IN Asthma (SABINA) III study. Patients were classified by investigator-defined asthma severity and practice type. Multivariable regression models analyzed the association between SABA prescriptions and clinical outcomes. Results: Of 1389 patients (mean age, 46.7 years; female, 69.5%), 85.7% had moderate-to-severe asthma and 88.7% were treated by specialists. Overall, 51.3% of patients experienced ≥1 severe asthma exacerbation in the previous 12 months, with 58.2% having partly controlled or uncontrolled asthma. Notably, 47.1% of patients were prescribed ≥3 SABA canisters (considered overprescription). SABA canisters were purchased over the counter by 15.3% of patients. Higher SABA prescriptions (vs 1–2 canisters), except 3–5 canisters, were associated with increased odds of uncontrolled asthma (p < 0.05). Conclusions: SABA overprescription occurred in almost half of all patients in the Middle East, underscoring the need for healthcare providers and policymakers to adhere to the latest evidence-based recommendations to address this public health concern. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/17476348.2022.2099841
dc.identifier.issn17476348
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12959
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd.
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectCohort Studies
dc.subjectCross-Sectional Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectMiddle East
dc.subjectTreatment Outcome
dc.subjectantibiotic agent
dc.subjectantihistaminic agent
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectleukotriene receptor blocking agent
dc.subjectlong acting drug
dc.subjectmonoclonal antibody
dc.subjectmuscarinic receptor blocking agent
dc.subjectnon prescription drug
dc.subjectshort acting drug
dc.subjectxanthine derivative
dc.subjectantiasthmatic agent
dc.subjectadolescent
dc.subjectadult
dc.subjectArticle
dc.subjectasthma
dc.subjectchild
dc.subjectclinical feature
dc.subjectclinical outcome
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectdisease control
dc.subjectdisease exacerbation
dc.subjectdisease severity
dc.subjectfemale
dc.subjecthuman
dc.subjectmaintenance therapy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectMiddle East
dc.subjectmonotherapy
dc.subjectobservational study
dc.subjectoverprescribing
dc.subjectyoung adult
dc.subjectasthma
dc.subjecttreatment outcome
dc.titleOverprescription of short-acting β2-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu